143 related articles for article (PubMed ID: 21771548)
1. Does the hepatocellular phase of gadobenate dimeglumine help to differentiate hepatocellular carcinoma in cirrhotic patients according to histological grade?
Tahir B; Sandrasegaran K; Ramaswamy R; Bertrand K; Mhapsekar R; Akisik FM; Saxena R
Clin Radiol; 2011 Sep; 66(9):845-52. PubMed ID: 21771548
[TBL] [Abstract][Full Text] [Related]
2. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging.
Gatto A; De Gaetano AM; Giuga M; Ciresa M; Siciliani L; Miele L; Riccardi L; Pizzolante F; Rapaccini GL; Gasbarrini A; Giuliante F; Vecchio FM; Pompili M; Bonomo L
Abdom Imaging; 2013 Aug; 38(4):736-44. PubMed ID: 22986351
[TBL] [Abstract][Full Text] [Related]
3. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
Lee EJ; Kim DJ; Cho ES; Kim KA
J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade.
Huang X; Xiao Z; Zhang Y; Lin N; Xiong M; Huang X; Chen Q; Cao D
J Comput Assist Tomogr; 2018; 42(3):365-372. PubMed ID: 29369947
[TBL] [Abstract][Full Text] [Related]
5. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
6. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
[TBL] [Abstract][Full Text] [Related]
8. Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI.
Rong D; Liu W; Kuang S; Xie S; Chen Z; Chen F; Xie Q; Luo Q; He B; Zhang Y; Deng Y; Yang H; Chen S; Wang J
Eur Radiol; 2021 Oct; 31(10):7584-7593. PubMed ID: 33860826
[TBL] [Abstract][Full Text] [Related]
9. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.
Marin D; Di Martino M; Guerrisi A; De Filippis G; Rossi M; Ginanni Corradini S; Masciangelo R; Catalano C; Passariello R
Radiology; 2009 Apr; 251(1):85-95. PubMed ID: 19332848
[TBL] [Abstract][Full Text] [Related]
11. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience.
Park Y; Kim SH; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ; Kim H; Koo JH; Lim HK
Korean J Radiol; 2010; 11(4):433-40. PubMed ID: 20592927
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
Kim HY; Choi JY; Kim CW; Bae SH; Yoon SK; Lee YJ; Rha SE; You YK; Kim DG; Jung ES
Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla.
Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI
J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184
[TBL] [Abstract][Full Text] [Related]
15. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
Kim JI; Lee JM; Choi JY; Kim YK; Kim SH; Lee JY; Han JK; Choi BI
Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
[TBL] [Abstract][Full Text] [Related]
16. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation.
Vogl TJ; Stupavsky A; Pegios W; Hammerstingl R; Mack M; Diebold T; Lodemann KP; Neuhaus P; Felix R
Radiology; 1997 Dec; 205(3):721-8. PubMed ID: 9393527
[TBL] [Abstract][Full Text] [Related]
18. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
19. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
20. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma.
Kim TK; Lee KH; Jang HJ; Haider MA; Jacks LM; Menezes RJ; Park SH; Yazdi L; Sherman M; Khalili K
Radiology; 2011 Jun; 259(3):730-8. PubMed ID: 21364083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
